Century Therapeutics (IPSC) Change in Accured Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.0 million, up 39.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 6.41% YoY), and the FY2025 annual result was -$4.3 million, down 369.35% from the prior year.
• Change in Accured Expenses declined to -$4.0 million in Q1 2026 per IPSC's latest filing, from $1.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.9 million in Q3 2023 and troughed at -$6.5 million in Q1 2025.
• A 5-year average of -$202470.6 and a median of $707000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 310.87% in 2023, then surged 397.06% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $1.1 million in 2022, then plunged by 310.87% to -$2.4 million in 2023, then surged by 221.74% to $2.9 million in 2024, then tumbled by 62.87% to $1.1 million in 2025, then slumped by 466.64% to -$4.0 million in 2026.
• Business Quant data shows IPSC's Change in Accured Expenses at -$4.0 million in Q1 2026, $1.1 million in Q4 2025, and $443000.0 in Q3 2025.